---
title: "Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress | SPTX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289044671.md"
description: "Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress | SPTX Stock News"
datetime: "2026-06-08T03:05:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289044671.md)
  - [en](https://longbridge.com/en/news/289044671.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289044671.md)
generator: "portal-rs"
---

# Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress | SPTX Stock News

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress | SPTX Stock News

### Related Stocks

- [SPTX.US](https://longbridge.com/en/quote/SPTX.US.md)

## Related News & Research

- [HC Wainwright Reaffirms Buy Rating for Seaport Therapeutics (NASDAQ:SPTX)](https://longbridge.com/en/news/298592169.md)
- [SPTX: Innovative oral neuropsychiatric therapies advance toward pivotal trials, backed by strong leadership](https://longbridge.com/en/news/298485305.md)
- [Seaport Therapeutics says Phase 1 trial shows GlyphAllo 375 mg does not impair next-morning driving vs placebo](https://longbridge.com/en/news/298444900.md)
- [Actuate Therapeutics to present at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/298504230.md)
- [Rapport Therapeutics CEO Abraham Ceesay sells $373,980 of common shares](https://longbridge.com/en/news/298498955.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**